Scholars Central

Conference abstractPublished 7 May 2018

Self-assembly PEGylation Retaining Activity (SPRA) technology via an interaction between cyclodextrin and adamantane: Application for insulin, lysozyme and bromelain

Authors: Taishi Higashi, Keiichi Motoyama, Hidetoshi Arima

Kumamoto University, Japan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Polyethylene glycol (PEG) modification (PEGylation) is one of the best approaches to improve the stabilities and blood halflives of protein drugs; however, PEGylation dramatically reduces the bioactivities of protein drugs. Here, we present âÂ?Â?selfassembly PEGylation retaining activityâÂ? (SPRA) technology via a hostâÂ?Â?guest interaction between PEGylated Ã?²-cyclodextrin (PEG-Ã?²-CyD) and adamantane-appended (Ad)-proteins. Firstly, we prepared SPRA-insulin and SPRA-lysozyme. Both SPRA-proteins showed high stability against heat and trypsin digest, comparable with that of covalently PEGylated protein equivalents. Importantly, the SPRA-lysozyme possessed ca. 100% lytic activity, whereas the activity of the covalently PEGylated lysozyme was ca. 23%. Additionally, SPRA-insulin provided a prolonged and peak-less blood glucose profile when compared with insulin glargine. It also showed no loss of activity. In contrast, the covalently PEGylated insulin showed a negligible hypoglycemic effect. Next, we prepared SPRA-bromelain, because bromelain is known to degrade the extracellular matrix (ECM) in pancreatic cancer and increase the penetration of antitumor agents, although the blood half-life of bromelain is short. SPRA-bromelain showed high in vitro ECM-degrading activity, and enhanced not only the accumulation of FITCdextran (2 MDa) in the tumor, but also the in vivo antitumor activities of doxorubicin and DOXIL. These findings indicate that SPRA technology has the potential as a generic method, surpassing conventional PEGylation methods for proteins. Recent Publications 1. Higashi T, Hirayama F, Misumi S, Arima H, Uekama K (2008) Design and evaluation of polypseudorotaxanes of PEGylated insulin with cyclodextrins as sustained release system. Biomaterials 29:3866-3871. 2. Higashi T, Li J, Song X, Zhu J, Taniyoshi M, Hirayama F, Iohara D, Motoyama K, Arima H (2016) Thermoresponsive formation of dimethyl cyclodextrin polypseudorotaxanes and subsequent one-pot synthesis of polyrotaxanes. ACS Macro Lett. 5:158-162. 3. Hirotsu T, Higashi T, Abu Hashim II, Misumi S, Wada K, Motoyama K, Arima H (2017) Self-assembly PEGylation Retaining Activity (SPRA) technology via a host-guest interaction surpassing conventional PEGylation methods of proteins. Mol. Pharm. 14:368-376. 4. Hirotsu T, Higashi T, Motoyama K, Arima H (2017) Cyclodextrin-based sustained and controllable release system of insulin utilizing the combination system of self-assembly PEGylation and polypseudorotaxane formation. Carbohydr. Polym. 15:42-48.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Pharmaceutical Regulatory Affairs: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutical Regulatory Affairs: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Taishi Higashi”
  • BylineArticles whose byline prints “Keiichi Motoyama”
  • BylineArticles whose byline prints “Hidetoshi Arima”